The Biological Operating System of Life: BioOS™
We made our discoveries by testing the hypothesis that living organisms contain code that controls files – an operating system. We assume that the genome is the code. Our technology is centered on the idea that RNA is both code and files.
The novel disease-specific RNA biomarkers that we have discovered are consistently expressed throughout the course of a chronic disease. The RNA sequences homologous to our proprietary database are biomarkers for neurologic diseases with very strong signal to noise.
Workflow
Fitting Right Into Current Lab Workflows
Product Demonstration
AACC Annual Meeting 2021
FBB Biomed Technology Featured Again at AACC Annual Meeting
RNA vs. DNA Diagnostics
RNA offers two key advantages over DNA: First, it is far more abundant than DNA in human tissue, which means it is easier to build more accurate diagnostics due to higher nucleic acid yield.
Second, due to RNA’s functional and regulatory role in molecular processes, RNA makes real-time diagnostics possible, while DNA only allows for risk stratification.
RNA Biomarkers
The advancement of sequencing hardware and bioinformatic software has enabled the discovery and utilization of ribonucleic acid (RNA) for diagnostic purposes.
We use a combination of proprietary sample enrichment and bioinformatic analysis to filter out and measure our FBB Biomed RNA biomarkers for neurologic diseases.
Research
Proof-of-Concept Studies
Background: Using the expression of disease-specific RNA biomarkers in RRMS patients to enable a differential diagnosis for RRMS
Publication #1: T. Wahls, M. Chimenti, J. Kamholz, and H. Urnovitz. (2020, May). “RNA Differential Expression In Serial Blood Samples Of Relapsing Remitting Multiple Sclerosis Patients Correlates With Clinically Reported Flares.” MULTIPLE SCLEROSIS JOURNAL, Vol. 26, No. 1_ SUPPL, pp. 81-81. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2020.
Publication #2: H. Urnovitz, L. Kaschmitter, D. Satish, H. Keen, M. Chimenti, H. Haenel, J. Kamholz, and T. Wahls (2022, May). “Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis.” MULTIPLE SCLEROSIS JOURNAL, Vol. 28, No. 1_ SUPPL, pp. 41-41. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2022.
RNA biomarkers over-expressed: Yes
Potential drug targets detected: Yes
Background: Using the expression of disease-specific RNA biomarkers in PD patients to enable a differential diagnosis for PD
Publication: H. Urnovitz, L. Kaschmitter, D. Satish, H. Keen, M. Chimenti, H. Haenel, J. Kamholz, and T. Wahls (2022, May). “Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis.” MULTIPLE SCLEROSIS JOURNAL, Vol. 28, No. 1_ SUPPL, pp. 41-41. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2022.
RNA biomarkers over-expressed: Yes
Potential drug targets detected: Yes
Background: Using the expression of disease-specific RNA biomarkers in AD patients to enable a differential diagnosis for AD
Publication: H. Urnovitz, L. Kaschmitter, D. Satish, H. Keen, M. Chimenti, H. Haenel, J. Kamholz, and T. Wahls (2022, May). “Newly Discovered Blood RNA Biomarkers in Relapsing Remitting Multiple Sclerosis Patients are Expressed Higher than in Patients with Alzheimer’s Disease, Parkinson’s Disease, or Amyotrophic Lateral Sclerosis.” MULTIPLE SCLEROSIS JOURNAL, Vol. 28, No. 1_ SUPPL, pp. 41-41. 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England: SAGE Publications Ltd, 2022.
RNA biomarkers over-expressed: Yes
Potential drug targets detected: Yes